Navigation Links
Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology

SAN DIEGO, May 25, 2011 /PRNewswire/ -- Ambrx Inc. today announced that data from a Phase 1/2 study, published online ahead of print on May 16 by Proceedings of the National Academy of Sciences, demonstrate the safety, efficacy and superior dosing frequency of ARX201, a sustained action human growth hormone, compared to therapy with native hormone.

The study evaluated adult GH-deficient (AGHD) patients treated with ARX201, which was generated with Ambrx's ReCODE™ technology. ARX201 was shown to have a half-life in patients of four days and to potentially be suitable for weekly dosing, which is superior to current therapy that requires daily dosing. Insulin-like growth factor 1 (IGF-1) a clinically validated biomarker of growth hormone activity was restored to normal ranges with weekly dosing.  ARX201 was found to be safe and well tolerated with repeat dosing.

"This report provides clinical validation of Ambrx technology, which constitutes site-directed protein medicinal chemistry," said Ho Cho, Ph.D., Chief Technology Officer of Ambrx. "ARX201 represents a best in class growth hormone optimized for efficacy, safety and patient convenience. Additionally, Ambrx has successfully scaled the manufacturing process to support advanced product development and eventual commercialization."

The study enrolled 22 AGHD patients who had not received growth hormone replacement therapy in the past six months.  Patients received weekly injections of ARX201 for up to 26 weeks.  ARX201 dose was determined through measurement of IGF-1, the standard indicator for growth hormone therapy.  Efficacy in patients included decreased truncal fat mass and total body fat, while lean body mass levels increased.

About ARX201

ARX201 is a long-acting rDNA-derived human GH drug candidate being developed by Ambrx for the treatment of growth hormone deficiencies. A Phase 2b clinical trial of ARX201 in adult patients with growth hormone deficiency was successfully completed in 2010. This and previous studies have demonstrated that ARX201 has improved pharmacological performance relative to existing growth hormone drugs, including the potential for much less frequent dosing.  ARX201 was generated through a process using Ambrx's ReCODE™ technology, which enables optimal protein medicinal chemistry. Through this approach, Ambrx discovered site specific mono-PEG hGH molecules optimized for potency and duration of action.  

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company using its transformational technology in discovery of best-in-class therapeutics, including antibody drug conjugates and novel proteins of unprecedented potential. The company is developing ARX201, a sustained action growth hormone that has successfully completed Phase 2b clinical trials. Ambrx has validated its biologics platform through partnerships with Eli Lilly, Merck-Serono, Pfizer, Roche and Merck & Co Inc.  Ambrx is advancing a robust portfolio of product candidates optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit

Media Contact:

David Schull or Ian Stone
Russo Partners
T: (212) 845-4271
T: (619) 528-2220

SOURCE Ambrx Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
2. Data Published in Proceedings of National Academy of Sciences Highlights Potential of Micromets BiTE Antibody Platform
3. London Genetics Conference Proceedings Published in Drug Discovery Today
4. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
5. Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians
6. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
7. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
10. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
11. Mayo Clinic Proceedings January Tip Sheet
Post Your Comments:
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... District , the only authorized OSHA Training Institute Education Center headquartered in Northern ... protecting their workers from extreme heat at their worksites. Employers with workers ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):